Circulating cell-free tumor DNA (ctDNA) can serve as a real-time biomarker of tumor burden
and provide unique insights into the evolving molecular landscape of cancers under the …

In the current era of precision medicine, the identification of genomic alterations has
revolutionised the management of patients with solid tumours. Recent advances in the …

Liquid biopsies are providing new opportunities for detection of residual disease in cell-free
DNA (cfDNA) after surgery but may be confounded through identification of alterations …

Background Currently available biomarkers are imperfect in their ability to predict responses
to the multiple first-line treatment options available for patients with advanced non-small cell …

Identifying locoregional gastric cancer patients who are at high risk for relapse after
resection could facilitate early intervention. By detecting molecular residual disease (MRD) …

With increasing knowledge on molecular tumour information, precision oncology has
revolutionised the medical field over the past years. Liquid biopsy entails the analysis of …

Simple Summary During the development and progression of lung tumors, processes such
as necrosis and vascular invasion shed tumor cells or cellular components into various fluid …

Liquid biopsy refers to the analysis of any tumour-derived material circulating in the blood or
any other body fluid. This concept is particularly relevant in lung cancer as the tumour is …

Simple Summary Lung cancer is the leading cause of cancer death worldwide. Detecting
lung malignancies promptly is essential for any anticancer treatment to reduce mortality and …

Simple Summary In recent years, the genetic landscape of hepatocellular carcinoma (HCC)
has been explored, identifying TERT promoter, CTNNB1, and TP53 as the most frequent …